Lokshin Vyacheslav, Omar Meruyert, Karibaeva Sholpan
Reproductive Health Department, International Clinical Centre of Reproduction "PERSONA", Almaty, Kazakhstan.
Department of Population Health and Social Sciences, Kazakhstan's Medical University School of Public Health, Almaty, Kazakhstan.
J Reprod Infertil. 2022 Jan-Mar;23(1):61-66. doi: 10.18502/jri.v23i1.8454.
The first child after fertilization (IVF) in the country was born in 1996. However, registering and recording data on assisted reproductive technologies (ARTs) in Kazakhstan is not mandatory. The purpose of the current study was to assess the treatment outcomes, availability, regulations, and ART cycles trends between 2011 and 2016.
Cycle-based data were collected from voluntarily participating ART centers and then descriptive analysis was performed. The study included 10470 ART cycles using different ART methods during 2011-2016. The availability rate of ART in the country was calculated by dividing the number of treatment cycles per million of the population.
The availability of ART per million inhabitants increased by 53.6%, from 236.9/million in 2011, to 364.0/million in 2016. In IVF cycles, clinical pregnancy rates (PRs) per aspiration remained stable, on average 37.1%. After ICSI, the average PR was 42.5%. In frozen embryo replacement cycles, there was an increase in the PR per transfer from 37.0% in 2011, to 42.5% in 2016, on average 39.2%.
Assisted reproductive technologies are developing rapidly in Kazakhstan; therefore, ART monitoring should be improved and become mandatory. Although the data is not yet representative, the most compelling evidence points to low access to ART. Since the use of ART in Central Asian countries is infrequent in comparison to European countries, there is a need to combine IVF data across different nations. This will allow for a deeper assessment of the scientific evidence and reduction of infertility burden through joint efforts.
该国首例体外受精(IVF)婴儿于1996年出生。然而,哈萨克斯坦对辅助生殖技术(ART)进行登记和记录数据并非强制性要求。本研究的目的是评估2011年至2016年间的治疗结果、可及性、监管情况以及ART周期趋势。
从自愿参与的ART中心收集基于周期的数据,然后进行描述性分析。该研究纳入了2011 - 2016年间使用不同ART方法的10470个ART周期。通过将每百万人口的治疗周期数相除来计算该国ART的可及率。
每百万居民的ART可及率提高了53.6%,从2011年的每百万236.9例增至2016年的每百万364.0例。在IVF周期中,每次抽吸的临床妊娠率(PRs)保持稳定,平均为37.1%。卵胞浆内单精子注射(ICSI)后,平均PR为42.5%。在冻融胚胎移植周期中,每次移植的PR从2011年的37.0%增至2016年的42.5%,平均为39.2%。
哈萨克斯坦的辅助生殖技术发展迅速;因此,应改进ART监测并使其成为强制性要求。尽管数据尚不具有代表性,但最有力的证据表明ART的可及性较低。由于与欧洲国家相比,中亚国家对ART的使用较少,有必要整合不同国家的IVF数据。这将有助于更深入地评估科学证据,并通过共同努力减轻不孕症负担。